Bannerman Wealth Management Group LLC Buys 1,338 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Bannerman Wealth Management Group LLC increased its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 96.2% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 2,729 shares of the biopharmaceutical company's stock after purchasing an additional 1,338 shares during the quarter. Alnylam Pharmaceuticals makes up 0.6% of Bannerman Wealth Management Group LLC's holdings, making the stock its 17th largest position. Bannerman Wealth Management Group LLC's holdings in Alnylam Pharmaceuticals were worth $737,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of ALNY. Truist Financial Corp lifted its position in Alnylam Pharmaceuticals by 136.6% during the fourth quarter. Truist Financial Corp now owns 4,398 shares of the biopharmaceutical company's stock worth $1,035,000 after acquiring an additional 2,539 shares during the last quarter. Ieq Capital LLC lifted its position in Alnylam Pharmaceuticals by 825.5% during the fourth quarter. Ieq Capital LLC now owns 38,806 shares of the biopharmaceutical company's stock worth $9,131,000 after acquiring an additional 34,613 shares during the last quarter. IFP Advisors Inc lifted its position in Alnylam Pharmaceuticals by 24.2% during the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 47 shares during the last quarter. Brighton Jones LLC acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth approximately $243,000. Finally, Silvercrest Asset Management Group LLC acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth approximately $1,151,000. 92.97% of the stock is owned by institutional investors.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 19,297 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $306.00, for a total value of $5,904,882.00. Following the completion of the sale, the chief executive officer now directly owns 48,948 shares of the company's stock, valued at approximately $14,978,088. The trade was a 28.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.50% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Trading Up 2.0%

ALNY stock traded up $6.09 during midday trading on Thursday, hitting $304.67. The stock had a trading volume of 874,326 shares, compared to its average volume of 931,682. The firm has a market cap of $39.73 billion, a P/E ratio of -140.40 and a beta of 0.22. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a 1-year low of $152.30 and a 1-year high of $310.22. The business has a fifty day moving average price of $268.41 and a two-hundred day moving average price of $258.64.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million for the quarter, compared to analyst estimates of $584.32 million. The firm's revenue for the quarter was up 20.2% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.16) EPS. On average, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on ALNY. Wells Fargo & Company raised their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a research report on Friday, March 21st. HC Wainwright reaffirmed a "buy" rating and set a $500.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, April 2nd. JPMorgan Chase & Co. raised their target price on shares of Alnylam Pharmaceuticals from $330.00 to $338.00 and gave the stock an "overweight" rating in a report on Thursday. Morgan Stanley lowered their target price on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a report on Friday, April 11th. Finally, William Blair reaffirmed an "outperform" rating on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. One analyst has rated the stock with a sell rating, four have given a hold rating and twenty-two have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $319.58.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.